"Phase III Clinical Trial of Botulax® to Treat Children With Cerebral Palsy"

PHASE3CompletedINTERVENTIONAL
Enrollment

144

Participants

Timeline

Start Date

March 31, 2012

Primary Completion Date

June 30, 2014

Study Completion Date

August 31, 2014

Conditions
Other Infantile Cerebral Palsy
Interventions
DRUG

Botulinum Toxin Type A(Botox®)

Single administration, 4units/kg body weight dose in patients with hemiplegia, 6units/kg body weight dose in patients with diplegia, Maximum dosage 200units

DRUG

Botulinum toxin type A(Botulax®)

Single administration, 4units/kg body weight dose in patients with hemiplegia,6units/kg body weight dose in patients with diplegia, Maximum dosage 200units

Trial Locations (6)

Unknown

St. Vincent's hospital, Suwon

Samsung medical center - Changwon, Changwon

Keimyung University Dongsan Medical Center, Daegu

Catholic university of Korea, Daejeon St. Mary's hospital, Daejeon

Samsung medical center - Seoul, Seoul

The Catholic University of Korea, Seoul St. Mary's hospital, Seoul

All Listed Sponsors
lead

Hugel

INDUSTRY

NCT01787344 - "Phase III Clinical Trial of Botulax® to Treat Children With Cerebral Palsy" | Biotech Hunter | Biotech Hunter